CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Raised to Hold at Wall Street Zen

CytomX Therapeutics (NASDAQ:CTMX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Several other brokerages have also recently weighed in on CTMX. Wedbush lifted their price target on CytomX Therapeutics from $11.00 to $12.00 and gave the company an “outperform” rating in a research report on Friday. Guggenheim decreased their price target on CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 10th. JPMorgan Chase & Co. reduced their price objective on shares of CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating for the company in a research note on Thursday, August 13th. Weiss Ratings restated a “sell (d)” rating on shares of CytomX Therapeutics in a report on Friday, September 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CytomX Therapeutics in a research report on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CytomX Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $12.00.

CytomX Therapeutics Stock Performance

Shares of CytomX Therapeutics stock opened at $2.19 on Friday. The stock’s fifty day moving average price is $2.71 and its 200-day moving average price is $3.81. CytomX Therapeutics has a 12 month low of $2.11 and a 12 month high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, November 5th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 38.46%. The firm had revenue of $1.69 million during the quarter, compared to analyst estimates of $10.38 million. On average, equities research analysts forecast that CytomX Therapeutics will post -0.40 earnings per share for the current year.

Institutional Trading of CytomX Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its stake in shares of CytomX Therapeutics by 1,064.3% during the first quarter. Bank of America Corp DE now owns 10,202,785 shares of the biotechnology company’s stock worth $47,953,000 after purchasing an additional 9,326,480 shares during the period. Canada Pension Plan Investment Board bought a new stake in CytomX Therapeutics during the second quarter valued at approximately $531,000. Wellington Management Group LLP grew its stake in shares of CytomX Therapeutics by 44.3% during the second quarter. Wellington Management Group LLP now owns 5,168,961 shares of the biotechnology company’s stock valued at $19,384,000 after buying an additional 1,585,976 shares during the last quarter. Stonepine Capital Management LLC acquired a new position in CytomX Therapeutics in the 2nd quarter worth about $768,750. Finally, BlackRock Inc. acquired a new position in CytomX Therapeutics during the 2nd quarter worth approximately $65,849,000. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics News Roundup

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $12 from $11 and maintained an Outperform rating, signaling continued optimism about CytomX’s prospects. Wedbush Raises Price Target
• Positive Sentiment: Varseta-M reported 20%–32% objective response rates and a seven-month median progression-free survival in late-line colorectal cancer. The program has FDA Fast Track designation, with pivotal-trial initiation planned for the first half of 2027. The company also had $367 million in cash and potential partnership milestones, although those milestones are contingent on future development and commercial progress. CytomX Stock Trading Near Cash Value
• Negative Sentiment: Third-quarter revenue was $1.69 million, well below analyst expectations of $10.38 million. CytomX reported a loss of $0.09 per share; one report characterized this as a $0.02-per-share miss against its consensus estimate. The revenue shortfall and continuing losses may weigh on sentiment. CytomX Q3 Results
• Negative Sentiment: The clinical-program outlook carries execution risk, and the cited analysis notes prior dilution and terminated legacy partnerships as concerns that have pressured revenue. CytomX Stock Trading Near Cash Value

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company’s approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites.

CytomX’s research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines.